

Market Announcement

29 April 2026

LTR Pharma Limited (ASX: LTP) – Trading Halt

Trading in the securities of LTR Pharma Limited ('LTP') will be halted at the request of LTP, pending the release of an announcement by LTP.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 1 May 2026; or
- the release of the announcement to the market.

LTP's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance



29 April 2026

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 45, South Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: tradinghaltsmelbourne@asx.com.au

Dear Melissa

TRADING HALT REQUEST – ASX CODE: LTP

In accordance with ASX Listing Rule 17.1, LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) requests an immediate trading halt be granted by the ASX with respect to the Company’s securities quoted on the Australian Securities Exchange.

Pursuant to ASX Listing Rule 17.1, the Company advises that:

1. The trading halt is necessary pending an analysis of data and an announcement by the Company in relation to the interim clinical (PK) trial results of its pivotal phase II study of SPONTAN® Nasal Spray treatment of Erectile Dysfunction;
2. LTR Pharma requests that the trading halt remain in place until the Company releases an announcement in relation to the analysis of interim clinical study data or until the commencement of trading on Friday 1 May 2026, whichever is earlier;
3. LTR Pharma confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

This request and announcement have been authorised for release by the Board of the Company.

Yours faithfully

Elizabeth Spooner
Joint Company Secretary



About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.



For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com